|Phone||+49 (0) 61 31 - 1 44 03 11|
|Series C, 5/2010 |
VRP Rhineland Palatinate Fund
Galantos Pharma GmbH focuses on the development of drugs for the treatment of Alzheimerâ€™s and other neurodegenerative diseases. It develops a drug for the treatment of mild-to-moderate Alzheimerâ€™s dementia. The company develops a technology platform that is suitable for screening and preclinical validation of drug candidates that are acting on cholinergic and other neuro-receptors and on various brain enzymes. The company was founded in 2005 and is based in Mainz, Germany.